12 results on '"Yen Hai Vu"'
Search Results
2. Factors relating to mortality in septic patients in Vietnamese intensive care units from a subgroup analysis of MOSAICS II study
- Author
-
Son Ngoc Do, Chinh Quoc Luong, Dung Thi Pham, My Ha Nguyen, Nga Thi Nguyen, Dai Quang Huynh, Quoc Trong Ai Hoang, Co Xuan Dao, Trung Minh Le, Ha Nhat Bui, Hung Tan Nguyen, Hai Bui Hoang, Thuy Thi Phuong Le, Lien Thi Bao Nguyen, Phuoc Thien Duong, Tuan Dang Nguyen, Yen Hai Vu, Giang Thi Tra Pham, Tam Van Bui, Thao Thi Ngoc Pham, Hanh Trong Hoang, Cuong Van Bui, Nguyen Minh Nguyen, Giang Thi Huong Bui, Thang Dinh Vu, Nhan Duc Le, Trang Huyen Tran, Thang Quang Nguyen, Vuong Hung Le, Chi Van Nguyen, Bryan Francis McNally, Jason Phua, and Anh Dat Nguyen
- Subjects
Medicine ,Science - Abstract
Abstract Sepsis is the most common cause of in-hospital deaths, especially from low-income and lower-middle-income countries (LMICs). This study aimed to investigate the mortality rate and associated factors from sepsis in intensive care units (ICUs) in an LMIC. We did a multicenter cross-sectional study of septic patients presenting to 15 adult ICUs throughout Vietnam on the 4 days representing the different seasons of 2019. Of 252 patients, 40.1% died in hospital and 33.3% died in ICU. ICUs with accredited training programs (odds ratio, OR: 0.309; 95% confidence interval, CI 0.122–0.783) and completion of the 3-h sepsis bundle (OR: 0.294; 95% CI 0.083–1.048) were associated with decreased hospital mortality. ICUs with intensivist-to-patient ratio of 1:6 to 8 (OR: 4.533; 95% CI 1.621–12.677), mechanical ventilation (OR: 3.890; 95% CI 1.445–10.474) and renal replacement therapy (OR: 2.816; 95% CI 1.318–6.016) were associated with increased ICU mortality, in contrast to non-surgical source control (OR: 0.292; 95% CI 0.126–0.678) which was associated with decreased ICU mortality. Improvements are needed in the management of sepsis in Vietnam such as increasing resources in critical care settings, making accredited training programs more available, improving compliance with sepsis bundles of care, and treating underlying illness and shock optimally in septic patients.
- Published
- 2021
- Full Text
- View/download PDF
3. The role of interleukin-24 in atopic dermatitis
- Author
-
Yen Hai Vu, Masutaka Furue, and Gaku Tsuji
- Subjects
atopic dermatitis ,interleukin-24 ,aryl hydrocarbon receptor ,tapinarof ,janus kinase inhibitor ,dupilumab ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Atopic dermatitis (AD) is characterized by skin barrier disruption, type 2 immune dysregulation, chronic pruritus, and abnormal colonization by Staphylococcus aureus (S. aureus). Tapinarof, an aryl hydrocarbon receptor modulator, has been demonstrated to attenuate the development of AD in clinical studies. Recently, we found that tapinarof upregulated the expression of filaggrin and loricrin, which are essential proteins in skin barrier functions. Paradoxically, tapinarof induced interleukin (IL)-24 secretion by normal human keratinocytes. IL-24 is produced by T helper 2 lymphocytes and keratinocytes following stimulation by type 2 cytokines, and IL-24 is upregulated in the skin of patients with AD. Furthermore, IL-24 contributes to skin barrier disruption and hyperplasia in AD, and it may exacerbate skin inflammatory responses, itch, and S. aureus infection. In this review, we summarized the current findings regarding the detrimental role of IL-24 in AD, thereby suggesting that co-treatment of tapinarof with therapeutics that block IL-24 signaling may represent a promising strategy for managing AD.
- Published
- 2021
- Full Text
- View/download PDF
4. IL-24 Negatively Regulates Keratinocyte Differentiation Induced by Tapinarof, an Aryl Hydrocarbon Receptor Modulator: Implication in the Treatment of Atopic Dermatitis
- Author
-
Yen Hai Vu, Akiko Hashimoto-Hachiya, Masaki Takemura, Ayako Yumine, Yasutaka Mitamura, Takeshi Nakahara, Masutaka Furue, and Gaku Tsuji
- Subjects
atopic dermatitis ,aryl hydrocarbon receptor ,tapinarof ,JAK inhibitor ,IL-24 ,filaggrin ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
Skin barrier dysfunction, including reduced filaggrin (FLG) and loricrin (LOR) expression, plays a critical role in atopic dermatitis (AD) development. Since aryl hydrocarbon receptor (AHR), a ligand-activated transcription factor, mediates keratinocyte differentiation, it is a potential target for AD treatment. Recently, clinical studies have shown that tapinarof, an AHR modulator, attenuated the development of AD. To examine the molecular mechanism involved in this, we analyzed tapinarof-treated normal human epidermal keratinocytes (NHEKs). Tapinarof upregulated FLG and LOR mRNA and protein expression in an AHR-dependent manner. Tapinarof also induced the secretion of IL-24, a cytokine that activates Janus kinase (JAK)-signal transducer and activator of transcription (STAT), leading to the downregulation of FLG and LOR expression. Knockdown of either IL-24 or STAT3 expression by small interfering RNA (siRNA) transfection augmented the upregulation of FLG and LOR expression induced by tapinarof, suggesting that inhibition of the IL-24/STAT3 axis during AHR activation supports the improvement of skin barrier dysfunction. Furthermore, tapinarof alone could restore the downregulation of FLG and LOR expression induced by IL-4, a key cytokine of AD, and its combination with JAK inhibitors enhanced this effect. These findings provide a new strategy for treating AD using AHR modulators and JAK inhibitors.
- Published
- 2020
- Full Text
- View/download PDF
5. IL-4 Augments IL-31/IL-31 Receptor Alpha Interaction Leading to Enhanced Ccl 17 and Ccl 22 Production in Dendritic Cells: Implications for Atopic Dermatitis
- Author
-
Sho Miake, Gaku Tsuji, Masaki Takemura, Akiko Hashimoto-Hachiya, Yen Hai Vu, Masutaka Furue, and Takeshi Nakahara
- Subjects
IL-31 ,IL-31 receptor alpha ,Ccl 17 ,Ccl 22 ,dendritic cell ,atopic dermatitis ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
Severe pruritus is a characteristic feature of atopic dermatitis (AD) and is closely related to its activity. Recent studies have shown that IL-31 is a key determinant of pruritus in AD. Anti-IL-31 receptor alpha (IL-31RA) antibody treatment has also been reported to improve pruritus clinically, subsequently contributing to the attenuation of AD disease activity. Therefore, IL-31 has been thought to be an important cytokine for regulating pruritus and AD disease activity; however, how IL-31 is involved in the immune response in AD has remained largely unknown. Epidermal Langerhans cells (LCs) and dermal dendritic cells (DCs) derived from bone marrow cells have been reported to play a critical role in AD pathogenesis. LCs and DCs produce Ccl 17 and Ccl 22, which chemoattract Th2 cells, leading to AD development. Therefore, we aimed to clarify how IL-31/IL-31RA interaction affects Ccl 17 and Ccl 22 production. To test this, we analyzed murine bone marrow-derived DCs (BMDCs) stimulated with IL-4, an important cytokine in AD development. We found that IL-31RA expression was upregulated by IL-4 stimulation in a dose-dependent manner in BMDCs. Furthermore, IL-31 upregulates Ccl 17 and Ccl 22 production in the presence of IL-4, whereas IL-31 stimulation alone did not produce Ccl 17 and Ccl 22. These findings suggest that IL-4 mediates IL-31RA expression and IL-31/IL-31RA interaction augments Ccl 17 and Ccl 22 production in BMDCs, which promotes Th2-deviated immune response in AD. Since we previously reported that soybean tar Glyteer, an aryl hydrocarbon receptor (AHR) ligand, impairs IL-4/Stat 6 signaling in BMDCs, we examined whether Glyteer affects IL-31RA expression induced by IL-4 stimulation. Glyteer inhibited upregulation of IL-31RA expression induced by IL-4 stimulation in a dose-dependent manner. Glyteer also inhibited Ccl 17 and Ccl 22 production induced by IL-4 and IL-31 stimulation. Taken together, these findings suggest that Glyteer treatment may improve AD disease activity by impairing IL-31/IL-31RA interaction in DCs.
- Published
- 2019
- Full Text
- View/download PDF
6. Factors relating to mortality in septic patients in Vietnamese intensive care units from a subgroup analysis of MOSAICS II study
- Author
-
Nhan Duc Le, Chi Van Nguyen, Hanh Trong Hoang, Tam Van Bui, Co Xuan Dao, Hai Bui Hoang, Thao Thi Ngoc Pham, Thang Dinh Vu, Bryan McNally, Dung Thi Pham, Nga T. T. Nguyen, Trung Le, Lien Thi Bao Nguyen, Anh Dat Nguyen, Thuy Thi Phuong Le, Cuong Van Bui, Jason Phua, Thang Quang Nguyen, Yen Hai Vu, Giang Thi Tra Pham, Phuoc Thien Duong, Son Ngoc Do, My Ha Nguyen, Quoc Trong Ai Hoang, Ha Nhat Bui, Trang Huyen Tran, Vuong Hung Le, Dai Quang Huynh, Chinh Quoc Luong, Tuan Dang Nguyen, Nguyen Minh Nguyen, Hung Tan Nguyen, and Giang Thi Huong Bui
- Subjects
Male ,medicine.medical_specialty ,medicine.medical_treatment ,Science ,Subgroup analysis ,Risk Assessment ,Article ,Sepsis ,Risk Factors ,Intensive care ,medicine ,Humans ,Hospital Mortality ,Renal replacement therapy ,Aged ,Mechanical ventilation ,Urinary tract infection ,Multidisciplinary ,Bacteria ,Antimicrobials ,business.industry ,Mortality rate ,Urological manifestations ,Odds ratio ,Middle Aged ,medicine.disease ,Health policy ,Health services ,Confidence interval ,Acute kidney injury ,Intensive Care Units ,Cross-Sectional Studies ,Vietnam ,Outcomes research ,Emergency medicine ,Infectious diseases ,Medicine ,Female ,Pathogens ,Infection ,business - Abstract
Sepsis is the most common cause of in-hospital deaths, especially from low-income and lower-middle-income countries (LMICs). This study aimed to investigate the mortality rate and associated factors from sepsis in intensive care units (ICUs) in an LMIC. We did a multicenter cross-sectional study of septic patients presenting to 15 adult ICUs throughout Vietnam on the 4 days representing the different seasons of 2019. Of 252 patients, 40.1% died in hospital and 33.3% died in ICU. ICUs with accredited training programs (odds ratio, OR: 0.309; 95% confidence interval, CI 0.122–0.783) and completion of the 3-h sepsis bundle (OR: 0.294; 95% CI 0.083–1.048) were associated with decreased hospital mortality. ICUs with intensivist-to-patient ratio of 1:6 to 8 (OR: 4.533; 95% CI 1.621–12.677), mechanical ventilation (OR: 3.890; 95% CI 1.445–10.474) and renal replacement therapy (OR: 2.816; 95% CI 1.318–6.016) were associated with increased ICU mortality, in contrast to non-surgical source control (OR: 0.292; 95% CI 0.126–0.678) which was associated with decreased ICU mortality. Improvements are needed in the management of sepsis in Vietnam such as increasing resources in critical care settings, making accredited training programs more available, improving compliance with sepsis bundles of care, and treating underlying illness and shock optimally in septic patients.
- Published
- 2021
7. pH-responsive nanocarriers for combined chemotherapies: a new approach with old materials
- Author
-
Chien Ngoc Nguyen, Yen Hai Vu, Thuan Thi Nguyen, Trong Bien Tran, Trung Quang Ngo, Nga Thi Bich Nguyen, Thien Giap Le, Thao Thi Do, Tuan Hiep Tran, Tung Bao Pham, and Quang Anh Luong
- Subjects
Drug ,Chromatography ,Polymers and Plastics ,media_common.quotation_subject ,technology, industry, and agriculture ,Excipient ,02 engineering and technology ,010402 general chemistry ,021001 nanoscience & nanotechnology ,01 natural sciences ,Controlled release ,0104 chemical sciences ,chemistry.chemical_compound ,Ethyl cellulose ,chemistry ,Paclitaxel ,In vivo ,Drug delivery ,medicine ,Nanocarriers ,0210 nano-technology ,media_common ,medicine.drug - Abstract
Ethyl cellulose (EC) is widely used in the pharmaceutical field as a polymeric excipient to fabricate sustained-release drug delivery systems. To develop a controlled release carrier exploiting the unique characteristic acidic environment of the target tumor site, this study examined the use of EC and lecithin (LC) as a nanoparticulated system. Paclitaxel and dihydroartemisinin were used as model drug combinations. The optimized formulated nanoparticles (NPs) of EC (EC NPs) and EC/LC (EC/LC NPs) were spherical and approximately 130 nm in diameter as determined by dynamic light scattering and electron microscopy analyses. The in vitro drug release from EC/LC NPs exhibited a pH-dependent pattern. In in vitro cell studies, the NPs were taken up by cells, and cell growth was inhibited by drugs released from the formulations. Most importantly, the in vivo anti-tumor study in mice showed a significant reduction in tumor volume after the intravenous administration of EC/LC NPs, suggesting the potential of using EC and LC as controlled and pH-sensitive drug delivery carriers.
- Published
- 2021
8. The <scp>IL</scp> ‐13– <scp>OVOL</scp> 1– <scp>FLG</scp> axis in atopic dermatitis
- Author
-
Takeshi Nakahara, Kazuhisa Furue, Dugarmaa Ulzii, Masutaka Furue, Gaku Tsuji, Yen Hai Vu, Takamichi Ito, and Makiko Kido-Nakahara
- Subjects
0301 basic medicine ,Immunology ,Inflammation ,Filaggrin Proteins ,Antibodies, Monoclonal, Humanized ,Dermatitis, Atopic ,Pathogenesis ,03 medical and health sciences ,0302 clinical medicine ,Intermediate Filament Proteins ,medicine ,Animals ,Humans ,Immunology and Allergy ,Lymphocytes ,Review Articles ,Skin ,Interleukin-13 ,business.industry ,Innate lymphoid cell ,Antibodies, Monoclonal ,Interleukin-4 Receptor alpha Subunit ,Atopic dermatitis ,medicine.disease ,Dupilumab ,Immunity, Innate ,Biological Therapy ,DNA-Binding Proteins ,030104 developmental biology ,Interleukin 13 ,medicine.symptom ,business ,Signal Transduction ,Transcription Factors ,030215 immunology ,Tralokinumab ,Filaggrin - Abstract
Despite sharing interleukin‐4 receptor α (IL‐4Rα) in their signaling cascades, IL‐4 and IL‐13 have different functions in atopic inflammation. IL‐13 preferentially participates in the peripheral tissues because tissue‐resident group 2 innate lymphoid cells produce IL‐13 but not IL‐4. In contrast, lymph node T follicular helper cells express IL‐4 but not IL‐13 to regulate B‐cell immunity. The dominant microenvironment of IL‐13 is evident in the lesional skin of atopic dermatitis (AD). The IL‐13‐rich local milieu causes barrier dysfunction by down‐regulating the OVOL1–filaggrin (FLG) axis and up‐regulating the periostin–IL‐24 axis. Genome‐wide association studies also point to the crucial involvement of the IL‐13, OVOL1 and FLG genes in the pathogenesis of AD. Biologics targeting IL‐13, such as the anti‐IL‐4Rα antibody dupilumab and the anti‐IL‐13 antibody tralokinumab, successfully improve AD lesions and further highlight the importance of IL‐13 in the pathogenesis of AD.
- Published
- 2019
9. Atopic Dermatitis and Type 2 Immune Deviation
- Author
-
Masutaka Furue, Takeshi Nakahara, Makiko Kido-Nakahara, Gaku Tsuji, Yen Hai Vu, and Dugarmaa Ulzii
- Subjects
Thymic stromal lymphopoietin ,business.industry ,medicine.medical_treatment ,Medicine (miscellaneous) ,Inflammation ,Atopic dermatitis ,medicine.disease ,Dupilumab ,Type 2 immune response ,030207 dermatology & venereal diseases ,03 medical and health sciences ,0302 clinical medicine ,Cytokine ,030228 respiratory system ,Immunology ,medicine ,Immunology and Allergy ,CCL26 ,medicine.symptom ,business ,Filaggrin - Abstract
To summarize recent topics on type 2 signatures in atopic dermatitis (AD). Therapeutic success of anti-IL-4 receptor antibody dupilumab does suggest that type 2 cytokines IL-4 and IL-13 have pivotal roles in the pathogenesis of AD. Lesional skin of AD expresses increased levels of IL-4 and IL-13. In parallel, type 2 chemokines such as CCL17, CCL22, and CCL26 are overexpressed in AD, and these chemokines recruit type 2 T cells and eosinophils. IL-4 and IL-13 downregulate the expression of filaggrin and exacerbate epidermal barrier dysfunction. Keratinocytes in barrier-disrupted epidermis produce thymic stromal lymphopoietin, IL-25 and IL-33, which enhance the type 2 immune response. IL-31, released from type 2 T cells, is an essential pruritogenic cytokine. IL-4 and IL-13 amplify the IL-31-mediated neuronal signal. Type 2 cytokines IL-4 and IL-13 are profoundly associated with three cardinal features of AD: barrier dysfunction, skin inflammation, and chronic pruritus. These findings explain the high efficacy of dupilumab in the treatment of AD.
- Published
- 2019
10. IL-4 Augments IL-31/IL-31 Receptor Alpha Interaction Leading to Enhanced Ccl 17 and Ccl 22 Production in Dendritic Cells: Implications for Atopic Dermatitis
- Author
-
Masaki Takemura, Masutaka Furue, Gaku Tsuji, Yen Hai Vu, Akiko Hashimoto-Hachiya, Sho Miake, and Takeshi Nakahara
- Subjects
0301 basic medicine ,medicine.medical_treatment ,Stimulation ,IL-31 ,lcsh:Chemistry ,030207 dermatology & venereal diseases ,0302 clinical medicine ,Receptor ,skin and connective tissue diseases ,lcsh:QH301-705.5 ,Spectroscopy ,biology ,integumentary system ,atopic dermatitis ,Chemistry ,Reverse Transcriptase Polymerase Chain Reaction ,General Medicine ,Flow Cytometry ,Computer Science Applications ,Cytokine ,Signal Transduction ,dendritic cell ,Enzyme-Linked Immunosorbent Assay ,Catalysis ,Article ,Dermatitis, Atopic ,Inorganic Chemistry ,03 medical and health sciences ,Immune system ,Downregulation and upregulation ,medicine ,Animals ,Physical and Theoretical Chemistry ,IL-31 receptor alpha ,Molecular Biology ,Interleukin 4 ,Interleukins ,Organic Chemistry ,Dendritic cell ,Dendritic Cells ,Receptors, Interleukin ,Aryl hydrocarbon receptor ,Ccl 22 ,body regions ,Mice, Inbred C57BL ,030104 developmental biology ,lcsh:Biology (General) ,lcsh:QD1-999 ,Ccl 17 ,Cancer research ,biology.protein ,Interleukin-4 - Abstract
Severe pruritus is a characteristic feature of atopic dermatitis (AD) and is closely related to its activity. Recent studies have shown that IL-31 is a key determinant of pruritus in AD. Anti-IL-31 receptor alpha (IL-31RA) antibody treatment has also been reported to improve pruritus clinically, subsequently contributing to the attenuation of AD disease activity. Therefore, IL-31 has been thought to be an important cytokine for regulating pruritus and AD disease activity, however, how IL-31 is involved in the immune response in AD has remained largely unknown. Epidermal Langerhans cells (LCs) and dermal dendritic cells (DCs) derived from bone marrow cells have been reported to play a critical role in AD pathogenesis. LCs and DCs produce Ccl 17 and Ccl 22, which chemoattract Th2 cells, leading to AD development. Therefore, we aimed to clarify how IL-31/IL-31RA interaction affects Ccl 17 and Ccl 22 production. To test this, we analyzed murine bone marrow-derived DCs (BMDCs) stimulated with IL-4, an important cytokine in AD development. We found that IL-31RA expression was upregulated by IL-4 stimulation in a dose-dependent manner in BMDCs. Furthermore, IL-31 upregulates Ccl 17 and Ccl 22 production in the presence of IL-4, whereas IL-31 stimulation alone did not produce Ccl 17 and Ccl 22. These findings suggest that IL-4 mediates IL-31RA expression and IL-31/IL-31RA interaction augments Ccl 17 and Ccl 22 production in BMDCs, which promotes Th2-deviated immune response in AD. Since we previously reported that soybean tar Glyteer, an aryl hydrocarbon receptor (AHR) ligand, impairs IL-4/Stat 6 signaling in BMDCs, we examined whether Glyteer affects IL-31RA expression induced by IL-4 stimulation. Glyteer inhibited upregulation of IL-31RA expression induced by IL-4 stimulation in a dose-dependent manner. Glyteer also inhibited Ccl 17 and Ccl 22 production induced by IL-4 and IL-31 stimulation. Taken together, these findings suggest that Glyteer treatment may improve AD disease activity by impairing IL-31/IL-31RA interaction in DCs.
- Published
- 2019
11. IL-24 Negatively Regulates Keratinocyte Differentiation Induced by Tapinarof, an Aryl Hydrocarbon Receptor Modulator: Implication in the Treatment of Atopic Dermatitis
- Author
-
Yasutaka Mitamura, Takeshi Nakahara, Gaku Tsuji, Yen Hai Vu, Masutaka Furue, Akiko Hashimoto-Hachiya, Ayako Yumine, and Masaki Takemura
- Subjects
Keratinocytes ,filaggrin ,0301 basic medicine ,Small interfering RNA ,Filaggrin Proteins ,lcsh:Chemistry ,030207 dermatology & venereal diseases ,0302 clinical medicine ,Intermediate Filament Proteins ,IL-24 ,loricrin ,Stilbenes ,STAT3 ,lcsh:QH301-705.5 ,Cells, Cultured ,Spectroscopy ,Gene knockdown ,atopic dermatitis ,biology ,aryl hydrocarbon receptor ,Chemistry ,Cell Differentiation ,General Medicine ,Computer Science Applications ,JAK inhibitor ,Loricrin ,Signal Transduction ,Filaggrin ,STAT3 Transcription Factor ,tapinarof ,Article ,Catalysis ,Dermatitis, Atopic ,Inorganic Chemistry ,03 medical and health sciences ,Downregulation and upregulation ,Humans ,Physical and Theoretical Chemistry ,Molecular Biology ,Janus Kinases ,Interleukins ,Organic Chemistry ,Membrane Proteins ,Resorcinols ,Aryl hydrocarbon receptor ,030104 developmental biology ,lcsh:Biology (General) ,lcsh:QD1-999 ,Receptors, Aryl Hydrocarbon ,biology.protein ,Cancer research ,Janus kinase - Abstract
Skin barrier dysfunction, including reduced filaggrin (FLG) and loricrin (LOR) expression, plays a critical role in atopic dermatitis (AD) development. Since aryl hydrocarbon receptor (AHR), a ligand-activated transcription factor, mediates keratinocyte differentiation, it is a potential target for AD treatment. Recently, clinical studies have shown that tapinarof, an AHR modulator, attenuated the development of AD. To examine the molecular mechanism involved in this, we analyzed tapinarof-treated normal human epidermal keratinocytes (NHEKs). Tapinarof upregulated FLG and LOR mRNA and protein expression in an AHR-dependent manner. Tapinarof also induced the secretion of IL-24, a cytokine that activates Janus kinase (JAK)-signal transducer and activator of transcription (STAT), leading to the downregulation of FLG and LOR expression. Knockdown of either IL-24 or STAT3 expression by small interfering RNA (siRNA) transfection augmented the upregulation of FLG and LOR expression induced by tapinarof, suggesting that inhibition of the IL-24/STAT3 axis during AHR activation supports the improvement of skin barrier dysfunction. Furthermore, tapinarof alone could restore the downregulation of FLG and LOR expression induced by IL-4, a key cytokine of AD, and its combination with JAK inhibitors enhanced this effect. These findings provide a new strategy for treating AD using AHR modulators and JAK inhibitors.
- Published
- 2020
12. Pathogenesis of Atopic Dermatitis: Current Paradigm.
- Author
-
Masutaka Furue, Dugarmaa Ulzii, Yen Hai Vu, Gaku Tsuji, Makiko Kido-Nakahara, and Takeshi Nakahara
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.